Zacks Research Research Analysts Raise Earnings Estimates for McKesson Co. (NYSE:MCK)

McKesson Co. (NYSE:MCK) – Research analysts at Zacks Research upped their FY2025 EPS estimates for shares of McKesson in a research note issued to investors on Monday, April 1st. Zacks Research analyst I. Bandyopadhyay now anticipates that the company will earn $30.83 per share for the year, up from their previous estimate of $30.78. The consensus estimate for McKesson’s current full-year earnings is $27.61 per share. Zacks Research also issued estimates for McKesson’s Q3 2026 earnings at $8.96 EPS and FY2026 earnings at $35.03 EPS.

A number of other research analysts also recently issued reports on MCK. Wells Fargo & Company initiated coverage on shares of McKesson in a research report on Thursday, December 14th. They issued an “equal weight” rating and a $502.00 price target on the stock. UBS Group increased their price target on McKesson from $575.00 to $620.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Citigroup boosted their price objective on McKesson from $530.00 to $575.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. StockNews.com cut McKesson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 4th. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of McKesson in a research report on Monday, February 26th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $522.21.

McKesson Price Performance

Shares of MCK opened at $535.00 on Wednesday. The business has a 50-day moving average of $517.95 and a 200-day moving average of $479.18. McKesson has a 1 year low of $352.34 and a 1 year high of $543.00. The company has a market capitalization of $70.30 billion, a price-to-earnings ratio of 24.24, a price-to-earnings-growth ratio of 1.45 and a beta of 0.45.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, February 7th. The company reported $7.74 earnings per share for the quarter, beating analysts’ consensus estimates of $7.05 by $0.69. The business had revenue of $80.90 billion during the quarter, compared to the consensus estimate of $77.93 billion. McKesson had a negative return on equity of 262.63% and a net margin of 0.99%. McKesson’s quarterly revenue was up 14.8% on a year-over-year basis. During the same period in the prior year, the business posted $6.90 earnings per share.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Douglass Winthrop Advisors LLC lifted its stake in McKesson by 1.4% during the fourth quarter. Douglass Winthrop Advisors LLC now owns 1,512 shares of the company’s stock worth $700,000 after purchasing an additional 21 shares during the last quarter. Addison Advisors LLC lifted its stake in shares of McKesson by 7.9% in the 4th quarter. Addison Advisors LLC now owns 299 shares of the company’s stock valued at $138,000 after purchasing an additional 22 shares during the period. Evergreen Wealth Solutions LLC increased its stake in shares of McKesson by 1.2% in the 4th quarter. Evergreen Wealth Solutions LLC now owns 1,931 shares of the company’s stock worth $894,000 after acquiring an additional 22 shares in the last quarter. Keystone Financial Services lifted its position in McKesson by 2.1% during the 4th quarter. Keystone Financial Services now owns 1,192 shares of the company’s stock valued at $552,000 after acquiring an additional 24 shares during the period. Finally, Carolinas Wealth Consulting LLC boosted its stake in McKesson by 42.9% during the fourth quarter. Carolinas Wealth Consulting LLC now owns 80 shares of the company’s stock worth $37,000 after acquiring an additional 24 shares in the last quarter. Institutional investors own 85.07% of the company’s stock.

Insider Activity at McKesson

In other news, CEO Brian S. Tyler sold 3,473 shares of the business’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $524.55, for a total value of $1,821,762.15. Following the transaction, the chief executive officer now owns 43,445 shares in the company, valued at approximately $22,789,074.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other McKesson news, EVP Leann B. Smith sold 186 shares of McKesson stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $496.00, for a total value of $92,256.00. Following the sale, the executive vice president now owns 1,511 shares of the company’s stock, valued at $749,456. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Brian S. Tyler sold 3,473 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $524.55, for a total value of $1,821,762.15. Following the transaction, the chief executive officer now directly owns 43,445 shares in the company, valued at approximately $22,789,074.75. The disclosure for this sale can be found here. 0.21% of the stock is owned by insiders.

McKesson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Friday, March 1st were issued a $0.62 dividend. The ex-dividend date was Thursday, February 29th. This represents a $2.48 annualized dividend and a dividend yield of 0.46%. McKesson’s dividend payout ratio is currently 11.24%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.